Search: L773:0957 5235 OR L773:1473 5733
> (2000-2004) >
Thrombin-induced pl...
-
Nylander, SvenCell Biology and Biochemistry, Precrinicar R and D, AstraZeneca R and D Mölndal, Mölndal, Sweden
(author)
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action
- Article/chapterEnglish2003
Publisher, publication year, extent ...
-
Ovid Technologies (Wolters Kluwer Health),2003
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-84280
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-84280URI
-
https://doi.org/10.1097/00001721-200302000-00007DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Thrombin-induced platelet activation involves cleavage of protease-activated receptors (PARs) 1 and 4, and interaction, via glycoprotein (Gp)Ibα, with the platelet GpIb/IX/V complex. This study investigated inhibition of platelet activation by thrombin inhibitors with different modes of action: two reversible direct thrombin inhibitors, melagatran and inogatran; hirudin, a tightly binding direct thrombin inhibitor; and two indirect thrombin inhibitors, heparin and dalteparin. Up-regulation of P-selectin (CD62P) and PAR-1 cleavage was measured in human whole blood, by flow cytometry. The thrombin concentration that induced 50% of maximum (EC50) PAR-1 cleavage was 0.028 nmol/l, while that of platelet activation (CD62P) was over two-fold higher (0.64 nmol/l). The EC50 of a PAR-1-independent component, defined as a further activating effect of thrombin on top of the maximum PAR-1-activating peptide (AP) effect, was 3.2 nmol/l. All anticoagulants were concentration-dependent inhibitors of thrombin-induced platelet activation and PAR-1 cleavage, but none inhibited PAR-1-AP or PAR-4-AP induced activation. Melagatran and inogatran were more potent inhibitors of CD62P up-regulation than of PAR-1 cleavage; conversely, hirudin, heparin and dalteparin were more potent inhibitors of PAR-1 cleavage.Thus, reversible direct thrombin inhibitors, such as melagatran, are potent inhibitors of thrombin-induced platelet activation, acting mainly by inhibition of a PAR-1-independent component.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Mattson, ChristerCell Biology and Biochemistry, Precrinicar R and D, AstraZeneca R and D Mölndal, Mölndal, Sweden
(author)
-
Cell Biology and Biochemistry, Precrinicar R and D, AstraZeneca R and D Mölndal, Mölndal, Sweden
(creator_code:org_t)
Related titles
-
In:Blood Coagulation and Fibrinolysis: Ovid Technologies (Wolters Kluwer Health)14:2, s. 159-1670957-52351473-5733
Internet link
Find in a library
To the university's database